Yahoo Finance

CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma ...
Mena FN

Cellcentric To Host Investor Event And Present Dose Optimization Data From Phase 2 Study Of Inobrodib For Multiple Myeloma At The American Society Of Hematology (ASH) Annual ...

(MENAFN- Newsfile Corp) - Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and ...
Finanznachrichten

CellCentric, Inc: CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma

Dose optimization will inform dose for registration studies Initial data expected by year end 2025 Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 9, 2025) - ...
Finanznachrichten

CellCentric, Inc: CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma ...